8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 22, 2010

Commission File No. 001-12575

UTAH MEDICAL PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

UTAH	87-0342734
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

7043 South 300 West

Midvale, Utah  84047

Address of principal executive offices

Registrant's telephone number:  (801) 566-1200

ITEM 8.01 OTHER EVENTS

On March 22, 2010, Utah Medical Products, Inc. issued a press release announcing the conclusion of a FDA Inspection to assess its compliance with the Quality System Regulation.  A copy of the press release is attached hereto as Exhibit 99.1

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	UTAH MEDICAL PRODUCTS, INC.
	REGISTRANT
Date:    3/22/10	By:	/s/ Kevin L. Cornwell
		Kevin L. Cornwell
		CEO

EXHIBIT INDEX

Index

Number                              Description

99.1 Press release issued March 22, 2010: Utah Medical Products, Inc. Announces Conclusion of FDA Inspection

EX-99.1

EXHIBIT 99.1

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that two FDA investigators have concluded a full QSIT inspectionused to assess a medical device manufacturer's compliance with the Quality System Regulation (QSR) and related regulations. The inspectional process, known as the "Quality System Inspection Technique" or QSIT, guides field investigators in conducting an efficient and effective comprehensive inspection, focusing on key elements of a firm's quality system.

FDA investigators use a Form FDA 483 to notify management in writing of significant objectionable observations which, in the investigator’s judgment, indicate a medical device is adulterated or prepared under conditions where the device may become adulterated.  At the conclusion of the UTMD inspection last Friday, the FDA investigators determined that there was no need to issue a Form FDA 483.  In the industry, this is known as a “clean” inspection and evidence that FDA investigators have concluded that the Company is in compliance with FDA requirements for manufacturing medical devices. UTMD appreciates the professionalism and objectivity of the recent investigators.

UTMD believes that this is significant since this inspection was the first FDA inspection of the Company since 2004.  After the 2004 inspection, the FDA filed a lawsuit against UTMD alleging that the Company had significant objectionable conditions. The lawsuit was adjudicated in Federal Court in 2005 with the Court concluding completely in UTMD’s favor and finding that UTMD’s quality system was in compliance with the QSR.

According to CEO Kevin Cornwell,

“For anyone – customers, potential customers, clinicians, hospital administrators and others in the medical device supply chain - who had doubts or concerns that the FDA had issues with UTMD’s quality system, the results of this recent inspection should lay those to rest. The millions of UTMD devices used in critical care situations with expected outcomes are clear evidence that UTMD’s quality system overall is working as intended in the QSR, and consistent with UTMD’s decades of commitment to excellence.”

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures, assembles and markets a broad range of disposable and reusable specialty medical devices.